IGF2BP1 and cancer: Moreover, the inhibition of IGF2BP1-RNA association by BTYNB proved beneficial in promoting the potency and/or efficacy of cancer therapeutics targeting IGF2BP1-driven effectors or pathways, as demonstrated for the CDK4/6 inhibitor palbociclip (Müller et al., 2020).